Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy
Open Access
- 1 September 2006
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 86 (9) , 927-939
- https://doi.org/10.1038/labinvest.3700445
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Candesartan: Nephroprotective effects and treatment of diabetic nephropathyDrugs of Today, 2003
- Diabetic nephropathy: It's in the numbersKidney International, 2002
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trialThe Lancet, 1998
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- The Extracellular Matrix in Diabetic NephropathyAmerican Journal of Kidney Diseases, 1993
- Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblastsAmerican Journal of Physiology-Cell Physiology, 1993
- Enhanced expression of “muscle-specific” actin in glomerulonephritisKidney International, 1992
- Structural-functional correlations in renal diseaseHuman Pathology, 1970